Held by 2 specialist biotech funds
No credit card required
**Signal Note: Driehaus Capital Initiates TFC-PR Position** This $660K position in Truist Financial's preferred shares is a portfolio diversification move by a growth-focused biotech allocator, not a biotech investment signal. TFC-PR offers fixed income characteristics (preferred equity) misaligned with Driehaus's typical growth equity strategy, suggesting either tactical cash management or balance sheet optimization rather than conviction on financial services or healthcare trends.
**Signal Note:** Eventide's initiation of a $2.0M position in TFC-PR (Truist Financial preferred shares) appears tangential to core biotech exposure and suggests portfolio diversification into fixed-income instruments rather than a biotech-specific catalyst. This move is inconsistent with Eventide's biotech-focused mandate and likely reflects opportunistic yield capture in preferred equity rather than company-specific pharmaceutical or medical device developments.